Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PDE4B | Q07343 | 5/20 | 0.44 |
| ▸ | HTR4 | Q13639 | 2/20 | 0.38 |
| ▸ | PDE4A | P27815 | 1/20 | 0.38 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.38 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | HTR3A | P46098 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153891 | 0.82 | PDE4A (0.41) | PDE4BHTR4PDE4APDE4CPDE4D | |
| SCHEMBL6153894 | 0.82 | PDE4A (0.41) | PDE4BHTR4PDE4APDE4CPDE4D | |
| SCHEMBL6153248 | 0.81 | HTR4 (0.51) | PDE4BHTR4PDE4APDE4CPDE4D | |
| SCHEMBL12316430 | 0.80 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4D | |
| SCHEMBL3876555 | 0.75 | GAA (0.53) | MEN1KMT2A | |
| SCHEMBL12099491 | 0.74 | PDE4B (0.55) | PDE4BPDE4D | |
| SCHEMBL12316429 | 0.70 | PDE4B (0.53) | PDE4BPDE4APDE4CPDE4DMEN1 | |
| SCHEMBL28838676 | 0.69 | SCN9A (0.47) | — | |
| SCHEMBL6156627 | 0.69 | PDE4B (0.52) | PDE4BPDE4APDE4CPDE4DMEN1 | |
| SCHEMBL1718762 | 0.69 | GAA (0.49) | MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | PDE4B 1288/4885HTR4 2642/4885PDE4A 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.